Tag: prevention

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...

ATLANTA, July 23, 2025 /PRNewswire/ -- The CDC Foundation today announced the recipients of two esteemed awards recognizing outstanding contributions to public health and health...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients

Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients

Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services MCLEAN, Va., July 22,...

Next-generation sports tech innovator teams up with NBATA to advance product testing, research, and development

Next-generation sports tech innovator teams up with NBATA to advance product testing, research, and development

Cato integrates the Cato SASE Cloud Platform with Microsoft Azure vWAN to simplify hybrid and multi-cloud networking for enterprises TEL AVIV, Israel, July 22, 2025...

Cato integrates the Cato SASE Cloud Platform with Microsoft Azure vWAN to simplify hybrid and multi-cloud networking for enterprises TEL AVIV, Israel, July 22, 2025...

European enterprise leaders collaborate with Bandwidth to combat fraud, shape regulatory readiness and build customer trust across AI-powered global communications. RALEIGH, N.C., July 22, 2025...

In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...

In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...